Placebo + E2007 + E2007
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson's Disease
Conditions
Parkinson's Disease
Trial Timeline
Nov 1, 2006 → Apr 1, 2008
NCT ID
NCT00360308About Placebo + E2007 + E2007
Placebo + E2007 + E2007 is a phase 3 stage product being developed by Eisai for Parkinson's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00360308. Target conditions include Parkinson's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00360308 | Phase 3 | Terminated |
Competing Products
20 competing products in Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 52 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 77 |
| Perampanel | Eisai | Phase 2 | 52 |